Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre-Clinical to Clinical Findings

• Type: Another Publication in an International Scientific Journal
• Date: 2021

Authors

Santana, W (Author) Other; de Oliveira, SSC (Author) Other; Ramos, MH (Author) Other; Santos, ALS (Author) Other; Dolabella, SS (Author) Other; Souto, EB (Author) Other; Severino, P (Author) Other; Jain, S (Author) Other

Journal

Title: Chemistry and Biodiversity

Vol. 18

ISSN: 1612-1872

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 0 Citations

Scientific classification

CORDIS: Health sciences

Other information

Authenticus ID: P-00V-9PV

DOI: 10.1002/cbdv.202100336

Abstract (EN): Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania. The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre-clinical (in vitro, in vivo), drug repurposing and clinical research.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 17